Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
March 26, 2024 16:01 ET
|
Galapagos NV
Mechelen, Belgium; 26 March 2024, 21:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that during its meeting of 26 March 2024, the Board of Directors appointed Mr. Dickinson as...
Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
February 22, 2024 16:01 ET
|
Frontier Medicines
Frontier Medicines Series C close and first patient dosed
Galapagos kondigt 2023 jaarresultaten en vooruitzichten 2024 aan
February 22, 2024 16:01 ET
|
Galapagos NV
Financiële kerngetallen voor het hele jaar 2023: Netto groepsomzet van €783,5 miljoen in 2023, inclusief €112,3 miljoen nettoverkopen voor Jyseleca® Geldmiddelen en kortlopende financiële...
Galapagos announces full year 2023 results and outlook for 2024
February 22, 2024 16:01 ET
|
Galapagos NV
Full year 2023 key financials: Group net revenues of €783.5 million, including Jyseleca® net sales of €112.3 million Cash and current financial investments of €3.7 billion on 31 December...
Galapagos presenteert op de jaarlijkse EBMT-EHA meeting van 2024
February 15, 2024 16:01 ET
|
Galapagos NV
Toont betekenisvolle vooruitgang in gedecentraliseerde CAR T-cel productie en presenteert translationele en klinische gegevens van lopende fase 1/2 CD19 CAR-T studies Mechelen, België; 15 februari...
Galapagos presents at EBMT-EHA annual meeting 2024
February 15, 2024 16:01 ET
|
Galapagos NV
Showcases meaningful advances in decentralized CAR T-cell manufacturing and presents translational and clinical data from ongoing Phase 1/2 CD19 CAR-T studies Mechelen, Belgium; 15 February 2024,...
NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
February 05, 2024 07:00 ET
|
NodThera
Se NodThera Ltd (“NodThera” or the “Company”) NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage...
Galapagos rondt transactie af om Jyseleca® business over te dragen aan Alfasigma
January 31, 2024 16:01 ET
|
Galapagos NV
Mechelen, België; 31 januari 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) heeft vandaag aangekondigd dat de transactie om haar Jyseleca® (filgotinib) activiteiten over te dragen aan...
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
January 31, 2024 16:01 ET
|
Galapagos NV
Mechelen, Belgium; 31 January 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the successful completion of the transaction to transfer its Jyseleca® (filgotinib) business...
Galapagos gaat strategische samenwerkingsovereenkomst aan met Thermo Fisher Scientific om gedecentraliseerd CAR-T productienetwerk in de VS verder uit te breiden
January 04, 2024 16:01 ET
|
Galapagos NV
Thermo Fisher Scientific gaat CAR-T productie- en kittingdiensten leveren voor Galapagos' point-of-care CAR-T kandidaat product in de San Francisco regioOvereenkomst volgt op eerder aangekondigde...